Sector: Pharma / Biotech
Platform: StartEngine
Stage: Early R&D
Minimum Investment: $497.49
🧩 What They Do
Ajna BioSciences is developing psychedelic-assisted treatments to revolutionize mental health care. Their pipeline includes plant-based psychedelics for conditions like depression, PTSD, and autism spectrum disorders, anchored by a pharmaceutical-grade cultivation and formulation platform.
📈 Why It Might Be the Next Big Thing
At the frontier of the $678B pharma market with plant medicines
Merges modern science with ancient healing wisdom
Strategic joint venture with Charlotte’s Web and BAT for developing botanical medicines
Entering Phase 2 clinical trials for ASD treatment
Raised over $27 million to advance their pipeline
📌 Snapshot
💵 Min. Investment: $497.49
📊 Growth Signal: Strong partnerships and progressing clinical trials
🧠 Founder Cred: Led by experts in botanical drug development and mental health treatment
🔎 My Take
Ajna BioSciences is at the cutting edge of integrating traditional plant-based therapies with modern pharmaceutical practices. Their focus on underserved areas in mental health and strategic collaborations position them as a potential leader in the emerging field of psychedelic medicine.